HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

ramosetron (Nasea)

structure given in first source

Also Known As:

Nasea; 5-((1-methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1H-benzimidazol; Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)-; YM 060; YM-060; YM060; ramosetron hydrochloride

Networked: 162 relevant articles (77 outcomes, 72 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Benzimidazoles: 111
    - ramosetron: 162

Experts

1.	Fujii, Yoshitaka: 15 articles (12/2011 - 01/2002)
2.	Tanaka, Hiroyoshi: 8 articles (01/2005 - 01/2002)
3.	Do, Sang-Hwan: 5 articles (09/2015 - 04/2010)
4.	Hirata, Takuya: 5 articles (05/2014 - 07/2007)
5.	Keto, Yoshihiro: 5 articles (05/2014 - 07/2007)
6.	Kwak, Young Lan: 4 articles (04/2014 - 08/2008)
7.	Ryu, Jung-Hee: 4 articles (01/2014 - 09/2011)
8.	Akuzawa, Shinobu: 4 articles (05/2009 - 07/2007)
9.	Funatsu, Toshiyuki: 4 articles (05/2009 - 07/2007)
10.	Sasamata, Masao: 4 articles (05/2009 - 07/2007)

Related Diseases

1.	Postoperative Nausea and Vomiting (PONV) 11/01/2011 - "Compared with placebo, the efficacy of 0.3 mg ramosetron in adults and 6 µg/kg in children were consistently beneficial in preventing PONV overall (RR: 0.4; 95% CI: 03-0.6). " 04/01/2011 - "Prophylactic therapy with ramosetron is effective for preventing PONV in adults and POV in children without clinically serious adverse effects." 09/01/2008 - "Ramosetron is effective for the long-term (up to 48 h) prevention of PONV. " 01/01/2006 - "Ramosetron is effective for the long-term (up to 48 hours) prevention of PONV. " 01/01/2005 - "Ramosetron is effective for the long-term prevention of PONV. "
2.	Vomiting 01/01/2015 - "This study shows a trend regarding the dose-response relationship for ramosetron to prevent CINV, including delayed emesis. " 12/01/2003 - "The number of emesis-free patients in the ramosetron 0.15-mg group and the placebo group were similar after both study periods. " 08/20/2005 - "The control rate of vomiting by ramosetron was 88%, 86% and 90% for the first three days. " 02/01/2004 - "Overall in 24 h, patients receiving oral ramosetron experienced no emesis slightly higher than that of the i.v. group (55% and 36% respectively, p = 0.05). " 01/01/2004 - "If vomiting occurred in the following 24 h, patients in both groups received an intravenous rescue dose of ramosetron 300 microg. "
3.	Nausea 06/01/2012 - "The ramosetron group tended to have a lower incidence of nausea with a higher complete response and tended to have less severe nausea and fewer rescue antiemetic requirements during the 6- to 24-hour period. " 08/01/2011 - "During the first 6 h, the severity of nausea and the use of rescue antiemetic medication were significantly lower in the ramosetron group. " 05/01/2010 - "The incidence of nausea between 2 and 24 h and the severity of nausea between 2 and 48 h were also less in the ramosetron group. " 08/20/2005 - "The effective rate of nausea by ramosetron was 82%, 72% and 84% for the first three days. " 10/01/2012 - "Ramosetron was also more effective in studies by Fujii et al.: vomiting 0.60 (0.39-0.91), p=0.02; nausea or vomiting 0.71 (0.56-0.91); p=0.006. "
4.	Neoplasms (Cancer) 07/01/2014 - "Thus, our results suggest that ramosetron can be administered safely, without gastrointestinal adverse effects, even to terminal cancer patients with delayed or accelerated gastric emptying abnormality." 06/01/1996 - "There was no evidence of a treatment-related effect on the incidence of any tumor or tumor type, and there were no non-neoplastic findings considered to be related to the administration of YM060. " 11/01/2012 - "Patients received palonosetron followed by ramosetron, and the antiemetic effects were evaluated by the Multinational Association of Supportive Care in Cancer Antiemesis Tool(MAT). " 12/01/2005 - "Thirty in-patients with malignant tumor being treated with cisplatin at a dose of 70 mg/m2 or more for a total of 94 cycles were scheduled to receive ramosetron 0. " 02/01/2009 - "Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer."
5.	Diarrhea 06/01/2014 - "We performed a randomized, double-blind, placebo-controlled trial to determine whether ramosetron reduces diarrhea in these patients. " 01/01/2013 - "In a double-blind, placebo-controlled, parallel-group study of 418 patients with diarrhea-predominant IBS-D, once-daily 5 μg and 10 μg doses of ramosetron increased the monthly responder rates of IBS symptoms compared to placebo. " 05/01/2014 - "Ramosetron is under evaluation for diarrhea-predominant IBS due to its acceptable safety and tolerability, besides its efficacy. " 04/01/2013 - "Is Ramosetron Really Useful to Treat Diabetic Diarrhea With Rapid Small Bowel Transit?: Author's Reply." 04/01/2013 - "Is ramosetron really useful to treat diabetic diarrhea with rapid small bowel transit?"

Related Drugs and Biologics

1.	Ondansetron (Zofran)
2.	Dexamethasone (Maxidex)
3.	Granisetron (Kytril)
4.	Cisplatin (Platino)
5.	Serotonin (5 Hydroxytryptamine)
6.	palonosetron (Aloxi)
7.	Antiemetics
8.	Propofol (Diprivan)
9.	tropisetron (Navoban)
10.	aprepitant (Emend)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Laparoscopic Cholecystectomy
3.	Thyroidectomy
4.	Patient-Controlled Analgesia (Analgesia, Patient Controlled)
5.	Gynecologic Surgical Procedures (Gynecologic Surgery)